Pharmacokinetics, Pharmacodynamics and Antiviral Efficacy of the MEK Inhibitor Zapnometinib in Animal Models and in Humans

• Main Authors: Julia Koch-Heier (Author), Annika Schönsiegel (Author), Lara Maria Waidele (Author), Julian Volk (Author), Yvonne Füll (Author), Christian Wallasch (Author), Sebastian Canisius (Author), Michael Burnet (Author), Oliver Planz (Author)
• Formato: Livro
• Publicado em: Frontiers Media S.A., 2022-06-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

The mitogen-activated protein kinase (MEK) inhibitor zapnometinib is in development to treat acute viral infections like COVID-19 and influenza. While the antiviral efficacy of zapnometinib is well documented, further data on target engagement/pharmacodynamics (PD) and pharmacokinetics (PK) are need...